RESUMO
Total knee arthroplasty (TKA) is one of the most frequent surgical procedures in orthopaedic surgery. Until now there have not been any standardized indication criteria, which might contribute to the large geographical differences in the frequency of TKA. This guideline aims to consent minimal requirements (main criteria), additional important aspects (minor criteria), as well as relative and absolute contraindications for TKA. The following main criteria have been consented: knee pain, radiological confirmation of osteoarthritis or osteonecrosis, inadequate response to conservative treatment, adverse impact of knee disease on the patient's quality of life and the burden of suffering due to the knee disease. Relative contraindications have been consented as severe general disease with reduced life expectancy and a BMI ≥40; absolute contraindications are an active infection and if the patient is not able to undergo major surgery.
Assuntos
Artroplastia do Joelho , Osteoartrite do Joelho , Humanos , Consentimento Livre e Esclarecido , Osteoartrite do Joelho/cirurgia , Guias de Prática Clínica como Assunto , Próteses e Implantes , Qualidade de VidaRESUMO
BACKGROUND: Medication-based strategies to treat rheumatoid arthritis are crucial in terms of outcome. They aim at preventing joint destruction, loss of function and disability by early and consistent inhibition of inflammatory processes. OBJECTIVE: Achieving consensus about evidence-based recommendations for the treatment of rheumatoid arthritis with disease-modifying anti-rheumatic drugs in Germany. METHODS: Following a systematic literature research, a structured process among expert rheumatologists was used to reach consensus. RESULTS: The results of the consensus process can be summed up in 6 overarching principles and 10 recommendations. There are several new issues compared to the version of 2012, such as differentiated adjustments to the therapeutic regime according to time point and extent of treatment response, the therapeutic goal of achieving remission as assessed by means of the simplified disease activity index (SDAI) as well as the potential use of targeted synthetic DMARDs (JAK inhibitors) and suggestions for a deescalating in case of achieving a sustained remission. Methotrexate still plays the central role at the beginning of the treatment and as a combination partner in the further treatment course. When treatment response to methotrexate is inadequate, either switching to or combining with another conventional synthetic DMARD is an option in the absence of unfavourable prognostic factors. Otherwise biologic or targeted synthetic DMARDs are recommended according to the algorithm. Rules for deescalating treatment with glucocorticoids and-where applicable-DMARDs give support for the management of patients who have reached a sustained remission. DISCUSSION: The new guidelines set up recommendations for RA treatment in accordance with the treat-to-target principle. Modern disease-modifying drugs, now including also JAK inhibitors, are available in an algorithm.
Assuntos
Antirreumáticos , Artrite Reumatoide , Alemanha , Glucocorticoides , Humanos , MetotrexatoRESUMO
On behalf of the Steering Committee of the German Society for Rheumatology, in 2016 the Interdisciplinary Commission on Healthcare Quality updated the 2008 memorandum on rheumatological healthcare in Germany. The update considers changes in therapeutic strategies, treatment targets as well as current structures in healthcare and the political framework. It concentrates on examination of the need for rheumatologists with a background in internal medicine and determines the gap between needs and supply. The internist rheumatologist is responsible for the care of patients with inflammatory rheumatic diseases and contributes to the care of patients with severe forms of other musculoskeletal diseases. At least 2 internist rheumatologists are needed for the outpatient care of 100,000 adult inhabitants, equivalent to 1350 rheumatologists in Germany. With currently 776 rheumatologists, we have little more than half of what we need. The German Society for Rheumatology calls for specific requirements planning for rheumatologists in outpatient care in order to decrease the deficit. In acute inpatient care we need specialized hospitals and wards that ensure a high quality of treatment for patients with complex diseases. We need up to 50 beds per 1 million inhabitants. At least 2 full-time internist rheumatologists and 3 further physicians are needed per 30 beds. In inpatient and outpatient rehabilitation we need 40 beds or outpatient places per 1 million inhabitants with at least 1 full-time rheumatologist and 1 further physician. In order to reduce the existing deficits and to cover the increasing future need for rheumatologists, more emphasis has to be laid on primary and secondary education. Chairs for internal rheumatology are needed at each medical university and more positions for postgraduate training in rheumatology should be provided. In all segments of healthcare the treatment aims should be jointly defined between patients and physicians. The patients should be treated in an interdisciplinary network, comprising other medical specialties, health professionals as well as patient organizations.
Assuntos
Assistência Ambulatorial/estatística & dados numéricos , Número de Leitos em Hospital/estatística & dados numéricos , Avaliação das Necessidades/estatística & dados numéricos , Doenças Reumáticas/epidemiologia , Doenças Reumáticas/terapia , Reumatologistas/provisão & distribuição , Reumatologia , Alemanha , Humanos , Prevalência , Reumatologistas/estatística & dados numéricos , Recursos HumanosRESUMO
The management of patients with spondyloarthritis (SpA) has experienced a paradigm shift in recent years. This is true for the treatment of axial as well as peripheral manifestations. International treat to target (T2T) recommendations for SpA based on the T2T strategy have now also been published, which contain 5 higher level principles (A-E) in addition to the 15 recommendations. In order to make the recommendations known and to promote national distribution, German experts have now issued a translation of the T2T recommendations for SpA into German.
Assuntos
Avaliação de Resultados em Cuidados de Saúde/normas , Planejamento de Assistência ao Paciente/normas , Assistência Centrada no Paciente/normas , Reumatologia/normas , Espondilartrite/diagnóstico , Espondilartrite/terapia , Tomada de Decisão Clínica , Medicina Baseada em Evidências , Alemanha , Humanos , Guias de Prática Clínica como Assunto , Tradução , Resultado do TratamentoAssuntos
Artrite Reumatoide/tratamento farmacológico , Artrite Reumatoide/imunologia , Monitoramento de Medicamentos/métodos , Glucocorticoides/administração & dosagem , Glucocorticoides/efeitos adversos , Anti-Inflamatórios/administração & dosagem , Anti-Inflamatórios/efeitos adversos , Antirreumáticos/administração & dosagem , Antirreumáticos/efeitos adversos , Artrite Reumatoide/diagnóstico , Relação Dose-Resposta a Droga , Esquema de Medicação , Medicina Baseada em Evidências , Humanos , Resultado do TratamentoRESUMO
In a joint initiative by the boards of the German Society for Rheumatology (DGRh) and the Association of Rheumatology Clinics (VRA) the European "standards of care" for rheumatoid arthritis, recently suggested by the European Musculoskeletal Conditions Surveillance and Information Network (eumusc.net) and supported by the European League Against Rheumatism (EULAR), were translated and annotated. The recommendations include aspects of the management of the disease, actual medical care, and access to information - this includes all types of support people with RA need, and, last but not least communication of the necessary knowledge. Furthermore, health care structures such as the availability of medical staff with relevant expertise are also important.
Assuntos
Artrite Reumatoide/diagnóstico , Artrite Reumatoide/terapia , Atenção à Saúde/normas , Guias de Prática Clínica como Assunto , Reumatologia/normas , Europa (Continente) , Medicina Baseada em Evidências , Alemanha , Humanos , Tradução , Resultado do TratamentoRESUMO
The German Association against Rheumatism and Arthritis considers the improvement of health literacy as one of their most important tasks. In local groups people with arthritis have the chance to exchange experiences and to benefit from consultation. Individual experiences are merged into a collective knowledge. Numerous printed media as well as information and exchange via the internet help to improve health literacy. Self-management courses and patient education courses are specific instruments to improve the competences of people with arthritis to manage their own condition. Through exercise programs, which are offered locally, the Association strives to improve self-efficacy regarding exercise. A survey of the members showed that the activities of the patient association are well accepted and valued. The empowered patient has more and more become a partner in the micro-level communication with their doctor. On the macro-level, patient representatives play an important role in the committees of the German self-administration of health insurance and physician organizations.
Assuntos
Letramento em Saúde/organização & administração , Promoção da Saúde/organização & administração , Educação de Pacientes como Assunto/métodos , Doenças Reumáticas/diagnóstico , Doenças Reumáticas/terapia , Reumatologia/organização & administração , Sociedades Médicas/organização & administração , Alemanha , HumanosRESUMO
INTRODUCTION: Peripheral arthritis is the most common presenting complaint in clinical rheumatology. Unequivocal identification of the underlying entity can be difficult, particularly at an early stage. Such cases are commonly referred to as undifferentiated peripheral inflammatory arthritis (UPIA). Since evidence-based recommendations for the clinical management of UPIA are lacking, this international 3e initiative convened 697 rheumatologists from 17 countries to develop appropriate recommendations. METHODS: Based on a systematic literature research in Medline, EMBASE, Cochrane Library, and the ACR/EULAR abstracts of 2007/2008, 10 multinational recommendations were developed by 3 rounds of a Delphi process. In Germany, a national group of experts worked on 3 additional recommendations using the same method. The recommendations were discussed among the members of the 3e initiative and the degree of consensus was analyzed as well as the potential impact of the recommendations on clinical practice. RESULTS: A total of 39,756 references were identified, of which 250 were systematically reviewed for the development of 10 multinational recommendations concerning differential diagnosis, diagnostic and prognostic value of clinical assessments, laboratory tests and imaging techniques, and monitoring of UPIA. In addition, 3 national recommendations on the diagnostic and prognostic value of a response to anti-inflammatory therapy on the analysis of synovial fluid and on enthesitis were developed by the German experts based on 35 out of 5542 references. CONCLUSIONS: The article translates the 2011 published original paper of the international 3e initiative (Machado et al., Ann Rheum Dis 70:15-24, 2011) and reports the methods and results of the national vote and the additional 3 national recommendations.
Assuntos
Artrite Reumatoide/diagnóstico , Artrite/diagnóstico , Medicina Baseada em Evidências , Idoso , Antirreumáticos/efeitos adversos , Antirreumáticos/uso terapêutico , Artrite/classificação , Artrite/tratamento farmacológico , Artrite Reumatoide/classificação , Artrite Reumatoide/tratamento farmacológico , Técnica Delphi , Diagnóstico Diferencial , Feminino , Alemanha , Humanos , Imageamento por Ressonância Magnética , Masculino , Valor Preditivo dos Testes , Prognóstico , UltrassonografiaRESUMO
Following the EULAR recommendations published in 2010 German guidelines for the medical treatment of rheumatoid arthritis were developed based on an update of the systematic literature search and expert consensus. Methotrexate is the standard treatment option at the time of diagnosis, preferably in combination with low dose glucocorticoids. Combined disease-modifying antirheumatic drugs (DMARD) therapy should be considered in patients not responding within 12 weeks. Treatment with biologicals should be initiated in patients with persistent high activity no later than 6 months after conventional treatment and in exceptional situations (e.g. early destruction or unfavorable prognosis) even earlier. If treatment with biologicals remains ineffective, changing to another biological is recommended after 3-6 months. In cases of long-standing remission a controlled reduction of medical treatment can be considered.
Assuntos
Algoritmos , Antirreumáticos/administração & dosagem , Artrite Reumatoide/diagnóstico , Artrite Reumatoide/tratamento farmacológico , Guias de Prática Clínica como Assunto , Reumatologia/normas , Antirreumáticos/efeitos adversos , Europa (Continente) , HumanosRESUMO
New therapeutic principles and considerable diagnostic advances have made it possible to define different rheumatic diseases and especially rheumatoid arthritis (RA) at an early stage and by starting an early and aggressive medication a considerable proportion of patients with RA will reach the status of low disease activity or even remission. With the additional development of composite measures to estimate the disease activity of RA, it was the goal of an international working group consisting of rheumatologists and patients to develop recommendations for treating rheumatoid arthritis in a similar way as for patients with hypertension or diabetes, with the aim to achieve remission as often as possible. This treat-to-target initiative has taken off in quite a number of different countries including Germany leading to discussions on how this initiative can be integrated into the specific national healthcare systems and what possibilities would exist for its implementation. To develop strategies for an improved healthcare of people suffering from rheumatic diseases and using RA as an example, action elements and postulates were developed which will be discussed in more detail in the present manuscript.
Assuntos
Antirreumáticos/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Doenças Endêmicas , Programas Nacionais de Saúde , Artrite Reumatoide/diagnóstico , Terapia Combinada , Comorbidade , Comportamento Cooperativo , Alemanha , Implementação de Plano de Saúde , Humanos , Comunicação Interdisciplinar , Melhoria de Qualidade , Indução de Remissão , Prevenção SecundáriaRESUMO
The international treat-to-target initiative including rheumatoid arthritis (RA) patients has defined remission or alternatively low disease activity as treatment goals. In Germany representatives of the medical profession, such as doctors, nurses and including the Deutsche Rheuma-Liga, are deliberating how to adapt and realize these goals in practice. The patient's perspective has to be taken into consideration as an outcome variable. Until now no combined patient reported outcome (PRO) score exists which is generally accepted by the scientific community and which puts the patient's perspective as the main primary outcome.Patients and doctors ought to decide jointly about the therapy goal remission/low disease activity and about other PROs and the planned strategy to achieve these goals. A precondition is that a sufficient timeframe is still available for this. The joint target of the medical profession and the Deutsche Rheuma-Liga is 1 rheumatologist per 50,000 adult inhabitants. An interdisciplinary and multidisciplinary treatment of RA patients is just as imperative as the expansion of patient training, information and self-management programs.
Assuntos
Antirreumáticos/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Satisfação do Paciente , Comportamento Cooperativo , Avaliação da Deficiência , Alemanha , Necessidades e Demandas de Serviços de Saúde , Humanos , Comunicação Interdisciplinar , Equipe de Assistência ao Paciente , Educação de Pacientes como Assunto , Indução de Remissão , Autocuidado , Resultado do TratamentoRESUMO
In 2010 a total of 9 guidelines on structural quality were endorsed by the Association of Rheumatology Clinics in Germany (VRA). These 9 structural criteria replace the regulations published in 2002 and were elaborated with the support of the German Rheumatology League. With guideline number 9 even the structural requirements for university hospitals are defined for the first time.Along with taking part in the quality project "Kobra" (continuous outcome benchmarking in rheumatology inpatient treatment) compliance with the new structural criteria constitutes a prerequisite for acquiring a quality certificate, which is awarded by an external institution.By this means the VRA sets the stage for its members to be prepared for future challenges and quality competition among hospitals. Furthermore, the provision of a high quality treatment for chronically diseased patients in rheumatology clinics will be effectively supported.
Assuntos
Fidelidade a Diretrizes/legislação & jurisprudência , Fidelidade a Diretrizes/organização & administração , Hospitais Especializados/legislação & jurisprudência , Hospitais Especializados/organização & administração , Garantia da Qualidade dos Cuidados de Saúde/legislação & jurisprudência , Garantia da Qualidade dos Cuidados de Saúde/organização & administração , Reumatologia/legislação & jurisprudência , Reumatologia/organização & administração , Benchmarking , Comportamento Cooperativo , Grupos Diagnósticos Relacionados/legislação & jurisprudência , Grupos Diagnósticos Relacionados/organização & administração , Alemanha , Hospitais Universitários , Humanos , Comunicação Interdisciplinar , Programas Nacionais de Saúde/legislação & jurisprudência , Equipe de Assistência ao Paciente/legislação & jurisprudência , Equipe de Assistência ao Paciente/organização & administração , Melhoria de Qualidade/legislação & jurisprudência , Melhoria de Qualidade/organização & administração , Indicadores de Qualidade em Assistência à Saúde , Mecanismo de Reembolso/legislação & jurisprudência , Mecanismo de Reembolso/organização & administraçãoRESUMO
Methotrexate (MTX) is one of the most commonly used drugs in the treatment of inflammatory rheumatic diseases. Unfortunately, MTX is an FDA Pregnancy Category X medication, which means it is contraindicated during pregnancy. The following review of the literature, with international guidelines, gives in addition an overview of current scientific knowledge on the topic. MTX is a teratogenic substance. It accesses the placenta and, for the dosage of 5 to 25 mg per week normally used in rheumatic diseases, can lead to both habitual abortions and anomalies in the neonate. Folic acid antagonism of MTX is the reason. In the rheumatologic setting, small case reports are available for the usage of MTX of 101 pregnant women at the time of conception or during pregnancy, mostly during the first trimester. Individual casuistry also exists. An abortion rate of 23% was found to result from these case reports. The anomaly rate for neonates was >5%. Only a few pregnancies with neonatal anomalies are described with the child's father taking MTX at the time of conception. MTX is taken up (in small amounts) by the mother's milk, and breast feeding under MTX therapy, therefore, is also contraindicated. Detailed and exact information on female patients taking MTX during the reproduction phase, but also for the father-to-be of the child if treated with MTX, with reference to the required contraception until at least three months before a planned conception and stopping of MTX at least at that time, is essential.
Assuntos
Anormalidades Induzidas por Medicamentos/etiologia , Aborto Espontâneo/induzido quimicamente , Antirreumáticos/efeitos adversos , Fertilidade/efeitos dos fármacos , Metotrexato/efeitos adversos , Doenças Reumáticas/tratamento farmacológico , Fatores Etários , Antirreumáticos/metabolismo , Aleitamento Materno/efeitos adversos , Contraindicações , Feminino , Conhecimentos, Atitudes e Prática em Saúde , Humanos , Masculino , Metotrexato/metabolismo , Leite Humano/metabolismo , Educação de Pacientes como Assunto , Guias de Prática Clínica como Assunto , Gravidez , Medição de Risco , Fatores de Risco , Resultado do TratamentoRESUMO
Inflammatory rheumatic diseases often affect females of childbearing age and pregnancy remains a challenge for this group of patients and their physicians. However, the majority of patients can now have successful pregnancies and deliver healthy babies as a result of our improved knowledge of the risks encountered during pregnancy, better preventive and therapeutic measures, and in particular close rheumatological, obstetric and neonatal monitoring. To ensure a favorable outcome, pregnancy should be planned to take place during a period of disease stability, monitored closely (physical examination, laboratory tests, and Doppler ultrasound), and treated appropriately.
Assuntos
Complicações na Gravidez/diagnóstico , Complicações na Gravidez/terapia , Doenças Reumáticas/diagnóstico , Doenças Reumáticas/terapia , Feminino , Humanos , GravidezAssuntos
Antirreumáticos/administração & dosagem , Antirreumáticos/efeitos adversos , Aleitamento Materno , Doenças do Tecido Conjuntivo/tratamento farmacológico , Complicações na Gravidez/induzido quimicamente , Complicações na Gravidez/tratamento farmacológico , Contraindicações , Inibidores de Ciclo-Oxigenase 2 , Feminino , Glucocorticoides/administração & dosagem , Glucocorticoides/efeitos adversos , Humanos , Exposição Materna/efeitos adversos , GravidezRESUMO
OBJECTIVES: To identify the main causes of morbidity and mortality in patients with antiphospholipid syndrome (APS) during a 5-year period and to determine clinical and immunological parameters with prognostic significance. METHODS: The clinical and immunological features of a cohort of 1000 patients with APS from 13 European countries who had been followed up from 1999 to 2004 were analysed. RESULTS: 200 (20%) patients developed APS-related manifestations during the 5-year study period. Recurrent thrombotic events appeared in 166 (16.6%) patients and the most common were strokes (2.4% of the total cohort), transient ischaemic attacks (2.3%), deep vein thromboses (2.1%) and pulmonary embolism (2.1%). When the thrombotic events occurred, 90 patients were receiving oral anticoagulants and 49 were using aspirin. 31/420 (7.4%) patients receiving oral anticoagulants presented with haemorrhage. 3/121 (2.5%) women with only obstetric APS manifestations at the start of the study developed a new thrombotic event. A total of 77 women (9.4% of the female patients) had one or more pregnancies and 63 (81.8% of pregnant patients) had one or more live births. The most common fetal complications were early pregnancy loss (17.1% of pregnancies) and premature birth (35% of live births). 53 (5.3% of the total cohort) patients died. The most common causes of death were bacterial infection (21% of deaths), myocardial infarction (19%) and stroke (13%). No clinical or immunological predictor of thrombotic events, pregnancy morbidity or mortality was detected. CONCLUSION: Patients with APS still develop significant morbidity and mortality despite current treatment (oral anticoagulants or antiaggregants, or both).
Assuntos
Síndrome Antifosfolipídica/epidemiologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Anticoagulantes/administração & dosagem , Síndrome Antifosfolipídica/tratamento farmacológico , Síndrome Antifosfolipídica/imunologia , Criança , Pré-Escolar , Uso de Medicamentos/estatística & dados numéricos , Métodos Epidemiológicos , Europa (Continente)/epidemiologia , Feminino , Humanos , Lactente , Recém-Nascido , Masculino , Pessoa de Meia-Idade , Prognóstico , Trombose/epidemiologia , Adulto JovemRESUMO
OBJECTIVE: To identify patterns of self-reported health problems relating to dose and duration of glucocorticoid intake in unselected patients with rheumatoid arthritis from routine practice. METHODS: Data from 1066 patients were analysed. The clinical status and drug treatment were reported by the physician, health problems during the past 6 months by the patient using a comprehensive list of symptoms. Patients with ongoing glucocorticoid treatment for more than 6 months and current doses of less than 5, 5-7.5 and over 7.5 mg/day prednisone equivalent were compared with a group without any glucocorticoid treatment for at least 12 months. RESULTS: The frequency of self-reported health problems was lowest in the group without glucocorticoid exposition and increased with dosage. Two distinct dose-related patterns of adverse events were observed. A "linear" rising with increasing dose was found for cushingoid phenotype, ecchymosis, leg oedema, mycosis, parchment-like skin, shortness of breath and sleep disturbance. A "threshold pattern" describing an elevated frequency of events beyond a certain threshold value was observed at dosages of over 7.5 mg/day for glaucoma, depression/listlessness and increase in blood pressure. Dosages of 5 mg/day or more were associated with epistaxis and weight gain. A very low threshold was seen for eye cataract (<5 mg/day). CONCLUSION: The associations found are in agreement with biological mechanisms and clinical observations. As there is a paucity of real-life data on adverse effects of glucocorticoids prescribed to unselected groups of patients, these data may help the clinician to adapt therapy with glucocorticoids accordingly and improve the benefit-risk ratio.
Assuntos
Artrite Reumatoide/tratamento farmacológico , Glucocorticoides/efeitos adversos , Coleta de Dados , Relação Dose-Resposta a Droga , Feminino , Glucocorticoides/administração & dosagem , Humanos , Masculino , Pessoa de Meia-Idade , Fatores de Risco , Fatores de TempoRESUMO
Rheumatic diseases can influence the reproduction, the course of pregnancy and the development of the fetus. The inflammatory rheumatic disease itself can be modulated in its activity in terms of amelioration or exacerbation of the rheumatic symptoms. The associations between rheumatic diseases and pregnancy will be illustrated with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and systemic lupus erythematosus as examples. Antirheumatic drug therapy during pregnancy and the breast feeding period has to be adapted critically.
Assuntos
Antirreumáticos/uso terapêutico , Complicações na Gravidez/fisiopatologia , Doenças Reumáticas/fisiopatologia , Síndrome Antifosfolipídica/complicações , Síndrome Antifosfolipídica/tratamento farmacológico , Síndrome Antifosfolipídica/fisiopatologia , Antirreumáticos/efeitos adversos , Artrite Psoriásica/imunologia , Artrite Reumatoide/tratamento farmacológico , Artrite Reumatoide/embriologia , Artrite Reumatoide/fisiopatologia , Contraindicações , Feminino , Humanos , Lúpus Eritematoso Sistêmico/complicações , Lúpus Eritematoso Sistêmico/embriologia , Lúpus Eritematoso Sistêmico/fisiopatologia , Gravidez , Complicações na Gravidez/tratamento farmacológico , Resultado da Gravidez , Doenças Reumáticas/tratamento farmacológico , Doenças Reumáticas/embriologia , Espondilite Anquilosante/fisiopatologiaRESUMO
OBJECTIVE: The prognosis of large-vessel GCA (LV-GCA) has not yet been investigated. How does it compare to GCA without arm vasculitis (GCA controls)? METHODS: Charts of 53 LV-GCA patients and 53 GCA controls were reviewed following a predetermined protocol. Telephone interviews of patients or their primary care physicians were conducted. Forty LV-GCA patients underwent follow-up duplex ultrasound examinations of proximal arm arteries. RESULTS: The mean observation time was 50 (s.d. +/- 31) months. None of the LV-GCA patients developed ischaemic arm complications. In 30%, proximal arm artery wall swelling disappeared completely. It decreased in 53%. In 8% it remained unchanged, in 5% it increased and in 5% arteries occluded with collateral flow. After the start of treatment, anterior ischaemic optic neuropathy developed neither in LV-GCA patients nor in GCA controls, amaurosis fugax occurred in 4 and 6%, arterial hypertension in 53 and 66%, strokes in 9 and 9%, myocardial infarction in 2 and 2%, diabetes mellitus in 30 and 25%, osteoporosis in 38 and 23%, and osteoporotic fractures in 15 and 4%, respectively. Mean corticosteroid dose was 3.7 mg/day. Mean duration of therapy was 42 months. All differences were insignificant. Four LV-GCA patients developed vasculitic popliteal artery stenoses. CONCLUSIONS: The prognosis of LV-GCA is benign with regard to ischaemic complications. Proximal artery wall swelling decreases in most cases. Its course is similar to GCA without proximal arm arteritis.